Static Chart Revive Therapeutics Ltd.

Equities

Delayed Canadian Securities Exchange Other stock markets 15:47:50 23/05/2024 BST			5-day change	1st Jan Change
0.025 ^CAD	0.00%		0.00%	-16.67%

04-23	FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	MT
04-23	Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	MT

Duration

Period